Chronic Heart Failure Clinical Trial
— OSICATOfficial title:
Optimisation de la Surveillance Ambulatoire Des Insuffisants CArdiaques Par Télécardiologie (OSICAT)
Verified date | September 2021 |
Source | CDM e-Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Targeted population: Patients with heart failure causing hospitalization during the last twelve months. Hypothesis: The number of all cause deaths and hospitalizations will be smaller for the Telecardiology group than for the reference group (standard follow-up care). An 18 months period of observation is required. Main goal: To compare the rate of all cause deaths and hospitalizations of patients with heart failure between the Telecardiology group and the reference group after 18 months of monitoring.
Status | Completed |
Enrollment | 990 |
Est. completion date | September 28, 2018 |
Est. primary completion date | December 20, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Aged 18 years or older - Men or women patient with heart failure having been hospitalized for cardiac decompensation during the last 12 months. - Patient with access to a wireline telephone service or GPRS network. - The patient is willing and able to sign an informed written consent - Patient is insured under the social security system Exclusion Criteria: - No available echocardiographic evaluation. - BNP lower than 100pg/ml or NT-proBNP lower than 300pg/ml - A prognosis of a life span of less than 12 months (apart from heart failure) - Dialysis patients - Heart transplant or cardiac assist devices - Patients involved in inotropic treatment - Patient doesn't have the necessary autonomy to use the equipment - Patient enrolled in another clinical trial - A pregnant or nursing woman, or patient of reproductive age who doesn't use contraceptives - Patients under tutorship, curatorship or judicial protection Inclusion Criteria in the extension period: Participation in the open extension period is only offered to patients who participated in the comparative period of the study, did not withdraw prematurely from the latter and gave their free informed written consent to participate to the extension period. |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier Universitaire d'Amiens de Picardie | Amiens | |
France | Centre Hospitalier Universitaire d'Angers | Angers | |
France | Centre Hospitalier Général d'Auch | Auch | Midi-Pyrénées |
France | Centre Hospitalier d'Avignon - Hospital Henri Duffaut | Avignon | |
France | Centre Hospitalier de Bastia | Bastia | |
France | Centre de réadaptation cardiovasculaire Midi-Gascogne | Beaumont de Lomagne | Midi-Pyrénées |
France | Centre Hospitalier de Béziers | Beziers | Languedoc-Roussillon |
France | Cabinet de Cardiologie - Pôle médical spécialisé | Béziers | Languedoc-Rousillon |
France | Centre Hospitalier Universitaire Bordeaux - Hôpital Saint André | Bordeaux | |
France | Centre Hospitalier Universitaire de Brest | Brest | |
France | Centre Hospitalier Universitaire de Lyon - Hôpital Louis Pradel | Bron | |
France | Centre Hospitalier de Cahors | Cahors | Midi-Pyrénées |
France | Centre Hospitalier Intercommunal Castres-Mazamet | Castres | Midi-Pyrénées |
France | Clinique des Cèdres | Cornebarrieu | Midi-Pyrénées |
France | Centre Hospitalier Universitaire François Mitterrand - Cardiologie 2 : Rythmologie et Insuffisance Cardiaque | Dijon | |
France | Centre Hospitalier Universitaire François Mitterrand - Cardiologie Générale | Dijon | |
France | Hôpital Léon Bérard | Hyères | |
France | Clinique de l'Union et du Vaurais | L'Union | Midi-Pyrénées |
France | Centre Hospitalier Universitaire de Grenoble - Hôpital Antoine Michallon | La Tronche | |
France | Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren | Limoges | |
France | Centre Hospitalier Universitaire de Marseille - Hôpital Nord | Marseille | |
France | Clinique du Pont de Chaume | Montauban | Midi-Pyrénées |
France | Centre Hospitalier Régional Universitaire de Montpellier | Montpellier | |
France | Cabinet libéral de Cardiologie du Muret | Muret | Midi-pyrenées |
France | Centre Hospitalier Universitaire de Nice - Hôpital Pasteur | Nice | |
France | Centre Hospitalier Universitaire Caremeau | Nîmes | |
France | Centre Hospitalier de Pau | Pau | |
France | Centre Hospitalier de Périgueux | Périgueux | |
France | Centre Hospitalier Universitaire Bordeaux - Hôpital Haut Lévêque | Pessac | |
France | Centre Hospitalier de Rodez | Rodez | Midi-Pyrénées |
France | Centre Hospitalier Intercommunal du Val d'Ariège | Saint-Jean-de-Verges | Midi-Pyrénées |
France | Cabinet libéral | St Yrieix la Perche | Limousin |
France | Polyclinique de l'Ormeau | Tarbes | Midi-Pyrénées |
France | Centre Hospitalier Intercommunal de Toulon - La Seyne-sur-Mer | Toulon | |
France | Centre Hospitalier Universitaire de Toulouse - Hôpital de Rangueil | Toulouse | Midi-Pyrénées |
France | Clinique Pasteur | Toulouse | Midi-Pyrénées |
France | Hôpital Joseph Ducuing | Toulouse | Midi-Pyrénées |
Martinique | Centre Hospitalier Universitaire de Martinique | Fort-de-France |
Lead Sponsor | Collaborator |
---|---|
CDM e-Health |
France, Martinique,
Galinier M, Roubille F, Berdague P, Brierre G, Cantie P, Dary P, Ferradou JM, Fondard O, Labarre JP, Mansourati J, Picard F, Ricci JE, Salvat M, Tartière L, Ruidavets JB, Bongard V, Delval C, Lancman G, Pasche H, Ramirez-Gil JF, Pathak A; OSICAT Investiga — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of All Causes Deaths and (Unplanned) Hospitalizations | Composite morbidity-mortality criterion combining the number of unplanned hospitalizations for any cause and deaths from any cause (adjudicated events) | 18 months | |
Primary | Number of All Causes Deaths and (Unplanned) Hospitalizations in NYHA Class III or IV Patients | Composite morbidity-mortality criterion combining the number of unplanned hospitalizations for any cause and deaths from any cause (adjudicated events) | 18 months | |
Primary | Number of All Causes Deaths and (Unplanned) Hospitalizations in Socially Isolated Patients | Composite morbidity-mortality criterion combining the number of unplanned hospitalizations for any cause and deaths from any cause (adjudicated events) | 18 months | |
Secondary | Time to First Unplanned Hospital Readmission or Death From Any Cause | Time to first unplanned hospital readmission (adjudicated events) or death from any cause, whichever occurred first in the subgroup of patients concerned | 18 months | |
Secondary | All Causes Deaths - Number of Patients Who Died From Any Cause | Number of patients who died from any cause | 18 months | |
Secondary | Time to Death From Any Cause | Time to death from any cause in the subgroup of patients who died | 18 months | |
Secondary | Number of Unplanned Hospitalizations for Any Cause | Number of unplanned hospitalizations for any cause (adjudicated events) | 18 months | |
Secondary | Number of Deaths and Unplanned Hospitalizations From Cardiovascular Cause | Composite morbidity-mortality criterion combining the number of cardiovascular unplanned hospitalizations and deaths from cardiovascular cause (adjudicated events) | 18 months | |
Secondary | Number of Unplanned Hospitalizations for Heart Failure | Number of unplanned hospitalizations for heart failure (adjudicated events) | 18 months | |
Secondary | Number of Unplanned Hospitalizations for Heart Failure in NYHA Class III or IV Patients | Number of unplanned hospitalizations for heart failure (adjudicated events) | 18 months | |
Secondary | Number of Unplanned Hospitalizations for Heart Failure in Socially Isolated Patients | Number of unplanned hospitalizations for heart failure (adjudicated events) | 18 months | |
Secondary | Time to First Unplanned Hospital Readmission for Heart Failure | Time to first unplanned hospital readmission for heart failure (adjudicated events) in the subgroup of patients concerned | 18 months | |
Secondary | Evolution of Quality of Life Assessed by Short Form-36 (SF-36) Questionnaire Scores | Evolution of Quality of Life assessed using absolute changes from baseline of each dimension and both component summary scores of SF-36 questionnaire. Indeed, SF-36 questionnaire include 8 general dimensions and 2 composite scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). They are standardized to range between 0 and 100. Higher scores on all SF-36 scales indicate more favorable levels of functioning and less disability. Thus, higher Physical Functioning scores reflect higher physical functioning. Higher Role Physical scores reflect lower limitations due to physical problems. Higher Bodily Pain scores reflect less bodily pain. Higher General Health scores reflect higher general health perception. Higher Vitality scores reflect higher vitality. Higher Social Functioning scores reflect higher social functioning. Higher Role Emotional scores reflect lower limitations due to emotional problems. Higher Mental Health scores reflect better mental health. | Between baseline and 12 months and between baseline and 18 months | |
Secondary | Annualized Number of Unplanned Hospitalizations for Any Cause During the Extension Period | Annualized number of unplanned hospitalizations for any cause according to investigators in patients hospitalized at least once during the extension period | Extension period until the marketing of the telemonitoring program (from 2 to 16 months, with an average of 9.5 months) | |
Secondary | Number of Patients Who Died From Any Cause During the Extension Period | Number of patients who died from any cause during the extension period | Extension period until the marketing of the telemonitoring program (from 2 to 16 months, with an average of 9.5 months) | |
Secondary | Annualized Number of Unplanned Hospitalizations From Cardiovascular Cause During the Extension Period | Annualized number of unplanned hospitalizations from cardiovascular cause according to investigators in patients hospitalized at least once for cardiovascular cause during the extension period | Extension period until the marketing of the telemonitoring program (from 2 to 16 months, with an average of 9.5 months) | |
Secondary | Number of Patients Who Died From Cardiovascular Cause During the Extension Period | Number of patients who died from cardiovascular cause according to investigators during the extension period | Extension period until the marketing of the telemonitoring program (from 2 to 16 months, with an average of 9.5 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03597646 -
The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure
|
N/A | |
Terminated |
NCT04065997 -
Apogee International
|
||
Withdrawn |
NCT03675113 -
Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02916160 -
Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
|
Phase 4 | |
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Completed |
NCT02268500 -
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
|
Phase 4 | |
Completed |
NCT02247245 -
The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.
|
N/A | |
Terminated |
NCT01906957 -
Cognition and Exercise Training
|
N/A | |
Completed |
NCT01919918 -
Muscle Afferent Feedback Effects in Patients With Heart Failure
|
Phase 1 | |
Not yet recruiting |
NCT01669395 -
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
|
N/A | |
Completed |
NCT00984529 -
Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
|
N/A | |
Recruiting |
NCT00863421 -
Sleep Disordered Breathing in Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02840565 -
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
|
Phase 1 | |
Completed |
NCT02441218 -
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
|
Phase 3 | |
Completed |
NCT00149409 -
Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT05532046 -
A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
|
Phase 1 | |
Recruiting |
NCT04984928 -
Readmission Risk of Patients With Heart Failure.
|
||
Completed |
NCT02814097 -
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Active, not recruiting |
NCT05560737 -
ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
|
||
Recruiting |
NCT03286127 -
Palliative Outcome Evaluation Muenster I
|